Bardet-Biedl syndrome (BBS)

What changes during this transition

Bardet-Biedl syndrome is a monogenic autosomal recessive ciliopathy caused by biallelic mutations in 25+ BBS genes encoding BBSome components (BBS1, BBS2, BBS4, BBS5, BBS7, BBS8/TTC8, BBS9, BBS18/BBIP10), chaperonin-related proteins (MKKS, BBS6, BBS10, BBS12), and other primary-cilium components. The disease driver is failure of primary-cilium signaling in tissues where cilia perform critical sensory or developmental functions — hypothalamic neurons (energy balance and the MC4R pathway), photoreceptors (vision), renal tubules (kidney function), heart, and limbs. Diagnosis follows clinical criteria (≥4 primary OR ≥3 primary + 2 secondary features) plus genetic testing — modern NGS panels identify the causative variant in roughly 80% of cohorts. Primary clinical features: progressive rod-cone retinal dystrophy (universal; often blindness by the third or fourth decade), post-axial polydactyly (~70%), early-onset childhood obesity with hyperphagia (MC4R-pathway driven through BBSome involvement), learning disabilities or intellectual impairment (variable), hypogonadism with delayed or incomplete puberty, and renal abnormalities — cystic kidney disease, tubular dysfunction, and progressive renal failure, the leading mortality driver in BBS, with many patients eventually requiring dialysis or transplant. Secondary features include speech and developmental delay, behavioral concerns, additional eye anomalies (nystagmus, strabismus, cataracts), brachydactyly or syndactyly, dental anomalies, ataxia, anosmia, mild facial dysmorphism, cardiac involvement (~10%), hepatic and GI manifestations, BBS-specific insulin resistance with metabolic syndrome, and hypertension. There is no cure; standard of care is comprehensive multidisciplinary management — ophthalmology surveillance and low-vision rehabilitation for retinal dystrophy plus cataract management, nephrology for renal disease (including dialysis and transplant when ESRD develops), endocrinology for hypogonadism (testosterone or estrogen + progesterone replacement) and diabetes, orthopedic management of polydactyly (early surgical correction is common), speech / OT / PT, behavioral and learning support, and cardiac evaluation. The major landmark in BBS-specific therapeutics is SETMELANOTIDE (Imcivree, Rhythm Pharmaceuticals — a MC4R agonist peptide), which received FDA approval in June 2022 for BBS-associated obesity in patients ≥6 years and was expanded to ≥2 years in 2024. It is the first FDA-approved therapy specifically for BBS-related obesity, and it is, transparently, a peptide therapy — but one whose mechanism (direct MC4R agonism addressing the hypothalamic pathway disrupted by BBSome dysfunction) is genuinely BBS-specific, whose Phase 3 trial demonstrated approximately 7% weight loss alongside meaningful hyperphagia reduction (the hyperphagia signal matters because hyperphagia drives much of the family-life impact of BBS obesity), and whose access pathway runs through specialty pharmacy, a REMS program, and Rhythm Pharmaceuticals' patient assistance — NOT through community peptide clinics. The Bardet-Biedl Syndrome Foundation (BBSFoundation.org) is the load-bearing patient advocacy organization and helps families navigate the setmelanotide access pathway, multidisciplinary care coordination, and genetic counseling. The Foundation Fighting Blindness is the relevant advocacy lane for the retinal dystrophy component, with ciliopathy gene therapy research ongoing (no approved gene therapy for BBS specifically yet, though adjacent ciliopathies have candidates in trial). Community peptides are not part of BBS management. The substrate entries on community peptides (BPC-157, NMN, the GH-axis trio, off-label GLP-1s) exist for honest /ask answers when patients or families encounter these in the general wellness or biohacking space — the editorial work is to honor setmelanotide's role as the standard-of-care peptide therapy without conflating it with community peptide framing, to flag the BBS-specific renal and ophthalmology considerations that community framings systematically miss, and to keep families pointed back at their BBS multidisciplinary team and the Bardet-Biedl Syndrome Foundation for the questions that matter. Sixty-fourth deliberate non-elevation of community peptides.